Next Article in Journal
Patient Indications for Mohs Micrographic Surgery: A Clinical Practice Guideline
Previous Article in Journal
A Multidisciplinary Perspective on the Subcutaneous Administration of Trastuzumab in HER2-Positive Breast Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 1
10.3747/co.26.4116
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer

by
S.A. Laurie
1,*,
S. Banerji
2,
N. Blais
3,
S. Brule
1,
P.K. Cheema
1,
P. Cheung
1,
N. Daaboul
3,
D. Hao
4,
V. Hirsh
3,
R. Juergens
1,
J. Laskin
5,
N. Leighl
1,
R. MacRae
1,
G. Nicholas
1,
D. Roberge
3,
J. Rothenstein
1,
D.J. Stewart
1 and
M.S. Tsao
1
1
The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa (Laurie), ON, Canada
2
Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
3
CHUM Cancer Centre, Université de Montréal, Montreal (Blais), QC, Canada
4
Tom Baker Cancer Centre and Department of Oncology, University of Calgary, Calgary, AB, Canada
5
British Columbia: Medical Oncology, BC Cancer, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(1), 81-93; https://doi.org/10.3747/co.26.4116
Submission received: 3 November 2018 / Revised: 12 December 2018 / Accepted: 8 January 2019 / Published: 1 February 2019

Abstract

Background: Little evidence has been generated for how best to manage patients with non-small-cell lung cancer (NSCLS) presenting with rarer clinical scenarios, including oligometastases, oligoprogression, and pseudoprogression. In each of those scenarios, oncologists have to consider how best to balance efficacy with quality of life, while maximizing the duration of each line of therapy and ensuring that patients are still eligible for later options, including clinical trial enrolment. Methods: An expert panel was convened to define the clinical questions. Using case-based presentations, consensus practice recommendations for each clinical scenario were generated through focused, evidence-based discussions. Results: Treatment strategies and best-practice or consensus recommendations are presented, with areas of consensus and areas of uncertainty identified. Conclusions: In each situation, treatment has to be tailored to suit the individual patient, but with the intent of extending and maximizing the use of each line of treatment, while keeping treatment options in reserve for later lines of therapy. Patient participation in clinical trials examining these issues should be encouraged.
Keywords: non-small-cell lung cancer, advanced; nsclc, advanced; oligometastatic disease; oligoprogression; pseudoprogression non-small-cell lung cancer, advanced; nsclc, advanced; oligometastatic disease; oligoprogression; pseudoprogression

Share and Cite

MDPI and ACS Style

Laurie, S.A.; Banerji, S.; Blais, N.; Brule, S.; Cheema, P.K.; Cheung, P.; Daaboul, N.; Hao, D.; Hirsh, V.; Juergens, R.; et al. Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. Curr. Oncol. 2019, 26, 81-93. https://doi.org/10.3747/co.26.4116

AMA Style

Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, et al. Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. Current Oncology. 2019; 26(1):81-93. https://doi.org/10.3747/co.26.4116

Chicago/Turabian Style

Laurie, S.A., S. Banerji, N. Blais, S. Brule, P.K. Cheema, P. Cheung, N. Daaboul, D. Hao, V. Hirsh, R. Juergens, and et al. 2019. "Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer" Current Oncology 26, no. 1: 81-93. https://doi.org/10.3747/co.26.4116

APA Style

Laurie, S. A., Banerji, S., Blais, N., Brule, S., Cheema, P. K., Cheung, P., Daaboul, N., Hao, D., Hirsh, V., Juergens, R., Laskin, J., Leighl, N., MacRae, R., Nicholas, G., Roberge, D., Rothenstein, J., Stewart, D. J., & Tsao, M. S. (2019). Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. Current Oncology, 26(1), 81-93. https://doi.org/10.3747/co.26.4116

Article Metrics

Back to TopTop